CD Bioparticles launches its AAV Vector Design services to support gene therapy and delivery.

(PRUnderground) July 21st, 2025

CD Bioparticles, a leading manufacturer and supplier of numerous drug delivery products and services, has announced the launch of its enhanced, one-stop AAV Vector Design services to support researchers in accelerating advancements in gene therapy and delivery, including the design, construction, and cloning of custom Adeno-Associated Virus (AAV) vectors, as well as professional virus packaging services.

Adeno-associated virus vectors are the leading gene delivery platform for treating a wide range of human diseases. Recent advances in developing clinically desirable AAV capsids, optimizing genome designs, and harnessing revolutionary biotechnologies have greatly contributed to the field of gene therapy. Preclinical and clinical successes in AAV-mediated gene replacement, gene silencing, and gene editing have popularized AAV as an ideal therapeutic vector. In fact, two AAV-based therapies have received regulatory approval in Europe and the United States. Ongoing research into AAV biology and a greater understanding of associated therapeutic challenges and limitations will pave the way for future clinical success.

CD Bioparticles now offers comprehensive, one-stop solutions for designing, constructing, and cloning custom AAV vectors, as well as specialized viral packaging services. The company’s experienced team of molecular biology and AAV specialists provides end-to-end support at every step, ensuring optimal transgene expression, efficient packaging, and precise in vivo targeting.

Key Services Provided:

1. Full Support on AAV Vector Design

• Design your gene of interest (GOI): Vectors will be designed based on the provided target gene and experimental requirements. CD Bioparticles can provide a wide range of vectors, including those for overexpression, CRISPR gene editing (sgRNA), shRNA, and miRNA. To ensure optimal knockdown or knockout efficiency, CD Bioparticles also offers sgRNA and shRNA selection and validation services.
• Cis Elements Selection: Assistance with selecting ITRs, Promoters, Enhancers, Introns, and PolyAs.
• Expression and Labeling Strategies: Options for small tags (HA, His, Flag), large fluorescent tags (EGFP, mCherry, TdTomato, Fluc, Rluc, Gluc, Cluc), and multiple gene expression strategies (multiple expression cassettes, IRES, T2A, P2A, fusion protein).
• AAV Serotype Selection: A wide range of AAV serotypes are offered, including common ones (AAV1, AAV2, AAV3B, AAV5, AAV6, AAV7, AAV8, AAV9, AAV11, AAV12, AAV13, AAV-DJ, AAVrh.10, AAVrh.74, AAV2-Retro) and engineered AAV capsids to provide distinct tropisms for various applications.

2. Synthesis of DNA fragments

• Design of gene of interest (GOI)
• Synthesis of DNA fragments
• Amplification of requested sequences

3. Molecular Cloning

• Cloning with standard cloning techniques, Gibson assembly or Gateway cloning.
• Multiple fragments can be assembled together simultaneously.

4. Strict Quality Control

• Restriction enzyme digestion to identify correct clones.
• SmaI/AdhI digestion to confirm two intact ITRs.
• Sanger sequencing to verify inserts.
• Whole plasmid sequencing available upon request.

5. Delivery

• The plasmid DNA (mini scale preparation) is delivered to the customer. Higher plasmid scales are available on request.
• Corresponding AAV vectors with any capsids can be produced within two weeks under the AAV Packaging Services.

To learn more about solutions for AAV Vector Design, please visit https://www.cd-bioparticles.net/services/aav-vector-design-services.html.

About CD Bioparticles

CD Bioparticles specializes in manufacturing and supplying nanoparticles, microparticles, and coatings for diagnostics and research, alongside developing customized, biocompatible drug delivery systems. We offer diverse formulation technologies (from liposomes to polymer nanoparticles) and comprehensive services, including surface functionalization, antibody immobilization, and contract research for drug delivery.

The post CD Bioparticles Announces Comprehensive AAV Vector Design Services to Advance Gene Therapy Research first appeared on

Original Press Release.